magAssist Recognized as a 2025 Potential Unicorn Enterprise in Jiangsu

Five Consecutive Years of Acknowledgment for Technological Progress and Industrialization Capability

The 2025 evaluation results for unicorn and gazelle enterprises has been recently released by the Jiangsu New Productivity Promotion Center. magAssist has once again been included in the “Jiangsu Potential Unicorn Enterprises” list, marking the fifth consecutive year of recognition.

This continued listing reflects magAssist’s sustained progress in developing advanced life support technologies and its ability to translate research into industrial applications over eight years of operation.

Since its establishment, magAssist has focused on addressing significant clinical needs in cardiovascular and multi-organ support. Rooted in a model that integrates medicine and engineering, the company brings together cross-disciplinary expertise in biomedical engineering, fluid dynamics, and system integration to advance next-generation life support solutions.

Core Product Platforms

• MoyoAssist® Extracorporeal VAD

  Applied in tertiary hospitals, the system provides circulatory support during high-risk PCI, acute heart failure management, and complex cardiovascular procedures. It is designed to maintain hemodynamic stability and support patients toward heart recovery or transplantation readiness.

• NyokAssist® Percutaneous VAD

  An expandable, minimally invasive device for short-term cardiac support. The device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), acknowledging its clinical potential.

• BreathMo® Portable ECMO System

  A fully magnetically levitated ECMO platform designed to enhance hemocompatibility, supporting both extracorporeal ventricular assistance and extracorporeal oxygenation in critical care settings.

Together, these platforms form an expanding product pipeline that spans heart failure management and multi-organ life support, with applications across different clinical scenarios and patient groups.

As magAssist continues to advance its engineering and clinical collaboration, it remains committed to advancing life support technology and contributing to the development of high-performance medical device capabilities.